Don't have an account?
The power of cardiac PET, unlocked with Flyrcado
The first and only F 18 PET MPI radiotracer advances cardiac PET
Proven clinical evidence: Flyrcado was associated with higher diagnostic certainty⁶
Clarity when it counts
Flyrcado's tracer kinetics advance the ability to detect the true extent of perfusion defects.⁷
High spatial resolution informs precise diagnosis, prognostic value, and creates superior image quality.
• Higher uptake in the myocardium than SPECT, resulting in exceptional image quality
• A higher extraction fraction allows for more accurate dynamic imaging, providing valuable clinical information
• Experience reliable detection of the extent and severity of ischemia
• A higher extraction fraction allows for more accurate dynamic imaging, providing valuable clinical information
• Experience reliable detection of the extent and severity of ischemia
- Flyrcado differences
The precision of PET MPI is excellent
PET MPI is recognized in Class I appropriate use criteria (AUC) recommendations for multiple patient populations
This includes challenging-to-image patient cohorts12,13
• Patients with a BMI over > 35
• Patients with dense breasts and breast implants
• Patients with multivessel CAD or microvascular disease
• Patients with diabetes
• Higher-risk patients for whom diagnostic errors carry greater clinical implications
• Patients with a BMI over > 35
• Patients with dense breasts and breast implants
• Patients with multivessel CAD or microvascular disease
• Patients with diabetes
• Higher-risk patients for whom diagnostic errors carry greater clinical implications
Cardiac PET advantage for clinical teams
Greater confidence in clinical decision-making
Improved risk stratification for complex patients
More precise downstream care planning, with the potential for fewer unnecessary tests or procedures
View patient profiles adapted from real clinical cases
- Patient 1
- Patient 2
- Patient 3
- Patient 4
- Patient 5
Comprehensive Support
Flyrcado Support Resources
• Flyrcado Support Line: 800 729 0701
• Medical Affairs: 800 654 0118
(option 2, then option 3) or medical.affairs@gehealthcare.com
• Pharmacovigilance: 800 654 0118
(option 2, then option 1) or gpv.drugsafety@gehealthcare.com
• Clinical Applications: support.miapps@gehealthcare.com
• Customer Service: 800 292 8514
• Medical Affairs: 800 654 0118
(option 2, then option 3) or medical.affairs@gehealthcare.com
• Pharmacovigilance: 800 654 0118
(option 2, then option 1) or gpv.drugsafety@gehealthcare.com
• Clinical Applications: support.miapps@gehealthcare.com
• Customer Service: 800 292 8514
Related products
Omni Legend
Omni Legend is the first system we're introducing on our
all-new, all-digital Omni platform.
FASTlab™ 2
FASTlab 2 radiochemistry systems feature a unique, integrated cassette-based design and GMP quality components to enable and ease the regulatory reliability and compliance in tracer production. Learn more about our FASTlab 2 radiochemistry systems.
Discovery MI Gen 2
A new generation of the world’s first digital PET/CT
platform.
References
- Martin, Seth S., et al. “Heart Disease and Stroke Statistics—2025 Update: A Report of US and Global Data from the American Heart Association.” *Circulation*, published online 27 Jan. 2025, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee.
- “Heart Disease." Centers for Disease Control and Prevention (CDC), 2025. https://www.cdc.gov/nchs/fastats/heart-disease.htm Accessed December 11, 2025 https://www.cdc.gov/nchs/fastats/heart-disease.htm
- "Heart Disease Facts." Centers for Disease Control and Prevention, 2023. https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html Accessed December 11, 2025.
- Joynt KE, Elkind MSV, Aparicio HJ, et al. Forecasting the Burden of Cardiovascular Disease and Stroke in the United States Through 2050—Prevalence of Risk Factors and Disease: A Presidential Advisory From the American Heart Association. Circulation. 2024;150(4). https://doi.org/10.1161/cir.0000000000001256
- Sayed, A, Al-Mallah, M. Geographic Proximity to Cardiac Positron Emission Tomography Facilities Across the United States. J Am Coll Cardiol Img. 2024 Dec, 17 (12) 1513–1515. https://doi.org/10.1016/j.jcmg.2024.07.019
- Bourque JM. Cardiac PET perfusion imaging: AURORA lights the way to a new era. J Am Coll Cardiol. 2023;82(16):1611-1613.
- Maddahi J, Packard RRS. Cardiac PET perfusion tracers: current status and future directions. Semin Nucl Med. 2014;44(5):333-343.
- Flyrcado (flurpiridaz F 18 injection). Full Prescribing Information. Arlington Heights, IL: GE HealthCare 2025.
- Maddahi J, Agostini D, Bateman TM, et al. Flurpiridaz F-18 PET Myocardial perfusion imaging in patients with suspected coronary artery disease. J Am Coll Cardiol. 2023;82(16):1598-1610.
- Patel KK, Singh A, Bateman TM. The potential of F-18 flurpiridaz PET/CT myocardial perfusion imaging for precision imaging. Curr Cardiol Rep. 2022;24(8):987-994.
- Driessen RS, Raijmakers PG, Stuijfzand WJ, Knaapen P. Myocardial perfusion imaging with PET. Int J Cardiovasc Imaging. 2017;33(7):1021-1031.
- Schindler TH, Bateman TM, Berman DS, et al. Appropriate use criteria for PET myocardial perfusion imaging. J Nucl Med. 2020;61(8):1221-1265.
- Bateman TM, Dilsizian V, Beanlands RS, DePuey EG, Heller GV, Wolinsky DA. American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET. J Nucl Med. 2016;57(10):1654-1656.
FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
- Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information.
- Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
Pregnancy
There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure
Lactation
Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.
Pediatric Use
Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch
IMPORTANT SAFETY INFORMATION
FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use important safety information
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
- Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information.
- Radiation risks: FLYRCADO contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Adverse Reactions Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
Pregnancy
There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure
Lactation
Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.
Pediatric Use
Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch